Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.55 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.55 |
| ▸ | DHODH | Q02127 | 4/20 | 0.52 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.46 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.46 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.46 |
| ▸ | GSK3B | P49841 | 2/20 | 0.43 |
| ▸ | CDC7 | O00311 | 1/20 | 0.43 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.43 |
| ▸ | PAK4 | O96013 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
| ▸ | CDK9 | P50750 | 1/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | MELK | Q14680 | 1/20 | 0.43 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.43 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.43 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24279936 | 0.91 | KEAP1 (0.55) | KEAP1NFE2L2DHODHCSNK2A1CSNK2A2 | |
| SCHEMBL894667 | 0.87 | MAPK9 (0.47) | KEAP1NFE2L2DHODHCSNK2A1CSNK2A2 | |
| SCHEMBL10550257 | 0.85 | DHODH (0.55) | DHODHCSNK2A1CSNK2A2CSNK2BGSK3B | |
| SCHEMBL10547236 | 0.83 | KEAP1 (0.53) | KEAP1NFE2L2DHODHCSNK2A1RAB9A | |
| SCHEMBL22833443 | 0.80 | KEAP1 (0.49) | KEAP1NFE2L2DHODHRAB9ASMN1; SMN2 | |
| SCHEMBL29383260 | 0.80 | KEAP1 (0.49) | KEAP1NFE2L2DHODHRAB9ASMN1; SMN2 | |
| SCHEMBL26047886 | 0.76 | KEAP1 (0.50) | KEAP1NFE2L2DHODH | |
| SCHEMBL27659429 | 0.76 | KEAP1 (0.50) | KEAP1NFE2L2DHODHDYRK1AMEN1 | |
| SCHEMBL15638933 | 0.75 | DHODH (0.64) | DHODHCSNK2A1CSNK2A2CSNK2BGSK3B | |
| SCHEMBL29536666 | 0.74 | KEAP1 (0.48) | KEAP1NFE2L2DHODHCSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2440204-B1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2013-12-18 | — | — | EP | disclosed |
| US-8586751-B2 | Nicotinamide compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-11-19 | — | — | US | disclosed |
| US-8586751-B2 | Nicotinamide compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-11-19 | — | — | US | disclosed |
| EP-2440204-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | Bristol-Myers Squibb Company (US) | 2012-04-18 | — | — | EP | disclosed |
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MEYERS SQUIBB COMPANY | 2012-04-05 | — | — | US | disclosed |
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MEYERS SQUIBB COMPANY | 2012-04-05 | — | — | US | disclosed |
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MEYERS SQUIBB COMPANY | 2012-04-05 | — | — | US | disclosed |
| WO-2010144647-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-12-16 | — | — | WO | disclosed |
| WO-2010144647-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | NADK, BTK, NAMPT | KEAP1 1497/4885NFE2L2 1423/4885DHODH 1470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.